SuperGen plans Orathecin NDA.(pancreatic cancer prep)(Brief Article)

SuperGen Inc. said it plans to begin filing a rolling new drug application by the end of the year for Orathecin, an oral chemotherapy compound for the treatment of pancreatic cancer. The news is the outgrowth of a positive meeting between SuperGen, of Dublin, Calif., and the FDA, Joseph Rubinfeld, SuperGen's chairman and CEO, said. He said the company will seek approval for patients who are refractory to available therapies. "This filing is crucial for SuperGen because it ratifies our existence in a sense because people have discounted us in the …